Molecular diagnostic company MatMaCorp (Materials and Machines Corporation) disclosed on Friday that its COVID-19 2SF RNA test is capable of detecting >99.5% of 3,801 coronavirus variants reported worldwide to date based on preliminary evaluation.
The company added that the data demonstrated the effectiveness of its COVID-19 2SF RNA test in detecting variants associated with SARS-CoV-2, the virus causing COVID-19. The 2SF RNA test can detect 99.7% of isolates for B.1.1.7 (UK variant), 99.8% of isolates for B.1.1.28 (Brazil variant), 100% of isolates for B.1.351 (South Africa variant), and 100% of isolates for B.1.525 (emerging global variant).
This COVID-19 2SF RNA test, performed on the company's Solas 8 portable detection system, was granted an EUA by the US FDA.
As of 17 February, all of the available information in global public databases show that the variations such as B.1.1.7, B.1.351, and P.1 do not show changes in the RdRp gene.
To identify the virus, the company said its COVID-19 test employs 'padlock probes', small bits of DNA targeted with high specificity toward the RNA-dependent RNA polymerase (RdRp) gene, an essential gene for viral replication. The RdRp gene has not accumulated significant changes in any of the COVID-19 strains so far.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT